119866 Apr 2026

The identifier is associated with several distinct official reports and professional records across different sectors. To provide the most helpful summary, please specify which of the following areas you are researching: 1. Pharmaceutical Research (FDA IND 119866)

This is the Investigational New Drug (IND) number for , an interleukin-13 receptor antagonist developed by Dermira Inc. (and later Eli Lilly) for treating moderate-to-severe atopic dermatitis.

A major 119,866-square-foot industrial facility was recently acquired by Chemplast , as reported by Colliers International. 119866

This refers to the published by the United Nations High Commissioner for Refugees (UNHCR) in October 2025.

Progressed through clinical trials, eventually leading to the FDA-approved product Ebglyss . The identifier is associated with several distinct official

ID 119866 is also linked to a global Catering Market Analysis report forecasting industry growth and share through 2035. 4. Public Records and Governance

The number is cited in Seattle City Council committee reports (Relating to Ordinance 119866) concerning utility appointments and public comments. (and later Eli Lilly) for treating moderate-to-severe atopic

It details findings regarding health services and community consultations for refugees, specifically in the Jordan region. 3. Commercial Real Estate & Market Research